Clinical Trials Logo

Clinical Trial Summary

In this study, the researchers want to learn more about the safety and effectiveness of Molidustat in Japanese men and women who have renal anemia, a condition in which the kidneys do not make enough of a hormone that helps the body make new red blood cells. In previous clinical trials with a small number of participants, several important adverse events were observed. The researchers in this study want to know how many patients also have these adverse events under the real world, and if the number of the red blood cells will be increased after the treatment of Molidustat. The researchers will collect the participants' health information from their medical records and their regular check-ups for up to 2 years. The data from this study will be submitted to the health authority in Japan in accordance with the local regulation.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04899661
Study type Observational
Source Bayer
Contact Bayer Clinical Trials Contact
Phone (+)1-888-84 22937
Email clinical-trials-contact@bayer.com
Status Recruiting
Phase
Start date August 6, 2021
Completion date September 30, 2027

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04925661 - HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia Phase 1
Active, not recruiting NCT03388385 - Acute Effects of Intravenous Iron on Oxidative Stress and Endothelial Dysfunction in Non-dialysis CKD Phase 4
Completed NCT05035641 - A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients Phase 2
Completed NCT02299661 - Pilot PK/PD Study of DS-1093a in Patients With Chronic Kidney Disease Phase 1
Active, not recruiting NCT05265325 - A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis Phase 2
Completed NCT05864261 - Pharmacokinetics Comparison Study of JT1801 and NESP® After Single Dose Administration in Chinese Health Male Volunteers Phase 4
Active, not recruiting NCT05085275 - Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease Phase 3
Completed NCT02708914 - Study to Compare the Safety and Efficacy of UB-851 and Eprex® Phase 3
Completed NCT02041208 - Variability of Hemoglobin Levels After Kidney Transplantation N/A
Not yet recruiting NCT04775615 - Multi-dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DDO-3055 Tablets in Healthy Subjects. Phase 1
Completed NCT00298441 - Efficacy of Intravenous Iron Administration in Hemodialysis Patients Phase 4
Active, not recruiting NCT04408820 - Post-marketing Surveillance of EVRENZO® Tablets (Roxadustat) in Patients With Renal Anemia
Completed NCT01543477 - Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia
Active, not recruiting NCT05951192 - A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney Disease Phase 4
Completed NCT04454879 - Different Doses of Roxadustat Treatment for Anemia in Peritoneal Dialysis Patients Phase 4
Recruiting NCT04360902 - Assessment of an Anemia Model Predictive Controller for Anemia Management in Hemodialysis Patients N/A
Not yet recruiting NCT03480178 - Renal Anemia Refractory to Erythropoietin
Completed NCT01306409 - Neocytolysis in the Treatment of Renal Anemia With Erythropoieses Stimulating Agents (ESA) Phase 4
Completed NCT00322413 - Comparison of Epoetin Alfa and Epoetin Omega in Anemic Dialysis Patients:Results of Efficacy Trial Phase 3
Recruiting NCT05970172 - A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease Phase 3